跳至主要内容
临床试验/jRCT2080222960
jRCT2080222960未知2 期

Phase II clinical study of HP-3150 in patients with low back pain.

Hisamitsu Pharmaceutical Co., Inc0 个研究点开始时间: 待定

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Multicenter, placebo-controlled, randomized,double-blind

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Patients in whom low back pain was diagnosed clinically

排除标准

  • Patients with abnormalities at the planned application site.
  • Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, heart failure, or another complication that is clinically problematic.
  • Patients who have undergone a procedure that may affect assessment of pain, including surgery, nerve block, or percutaneous laser disc decompression, within six months before giving informed consent.
  • Patients with pain attributable to a complication whose low back pain cannot be assessed properly.

研究者

相似试验